Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT06013111	TitleAn Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors	Fase Fase 1	Date Added 2023-08-28	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05438342	TitleAn Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis	Fase No aplicable	Date Added 2022-06-29	Ubicación China	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas Chemotherapy，checkpoint immunotherapy, targeted therapy	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03692429	TitlealloSHRINK - Régimen estándar de quimioterapia e inmunoterapia con células T receptoras de antígenos quiméricos CYAD-101 alogénicas basadas en NKG2D.	Fase Fase 1	Date Added 2018-10-02	Ubicación Florida, United States Bélgica	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas CYAD-101, FOLFIRI, FOLFOX	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03935893	TitleTransferencia adoptiva de linfocitos infiltrantes tumorales para cánceres sólidos avanzados	Fase Fase 2	Date Added 2019-05-02	Ubicación Pennsylvania, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Fludarabine + Cyclophosphamide combination, Tumor Infiltrating Lymphocytes (TIL)	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03296137	TitleAdoptive Cell Therapy Across Cancer Diagnoses	Fase Fase 1/Fase 2	Date Added 2017-09-28	Ubicación Dinamarca	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy	Etiquetas MSS/ MMRp
NCT ID NCT03412877	TitleAdministración de células T autólogas modificadas genéticamente para expresar receptores de células T reactivos contra neoantígenos en personas con cáncer metastásico	Fase Fase 2	Date Added 2018-01-29	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas Aldesleukin, Cyclophosphamide, Fludarabine, Individual Patient TCR-Transduced PBL, Pembrolizumab (Keytruda)	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03190941	TitleAdministración de linfocitos de sangre periférica transducidos con un receptor murino de células T que reconoce la variante G12V del RAS mutado en pacientes HLA-A*11:01	Fase Phase 1, Phase 2	Date Added 2017-06-19	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Anti-KRAS G12V mTCR PBL, Cyclophosphamide, Fludarabine, High-dose Aldesleukin	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03745326	TitleAdministración de linfocitos de sangre periférica transducidos con un receptor murino de células T que reconoce la variante G12D del RAS mutado en pacientes HLA-A*11:01	Fase Phase 1, Phase 2	Date Added 2018-11-19	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03280511	TitleQuimioterapia adyuvante con aerosol intraperitoneal presurizado (PIPAC) en pacientes con cáncer de colon de alto riesgo resecado	Fase Fase 2	Date Added 2017-09-12	Ubicación Dinamarca	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas PIPAC	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05382741	TitleAdjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial	Fase Fase 2	Date Added 2022-05-19	Ubicación Italia	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga	Etiquetas MSS/ MMRp

Showing 231 to 240 of 299 entries